Ani Pharmaceuticals (ANIP) Cash from Investing Activities (2010 - 2026)

Ani Pharmaceuticals has disclosed Cash from Investing Activities across 17 years of filings, most recently posting -$11.3 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$11.3 million, up 42.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$25.8 million (up 94.05% YoY), and the FY2025 annual result was -$34.3 million, up 91.52% from the prior year.
• Cash from Investing Activities came in at -$11.3 million for Q1 2026 at Ani Pharmaceuticals, down from -$1.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $8.9 million in Q1 2024 to a low of -$398.5 million in Q3 2024.
• The 5-year median for Cash from Investing Activities is -$4.8 million (2023), against an average of -$28.5 million.
• Peak annual rise in Cash from Investing Activities reached 479.64% in 2024, while the deepest fall reached 8652.95% in 2024.
• Ani Pharmaceuticals' Cash from Investing Activities stood at -$3.1 million in 2022, then sank by 52.1% to -$4.8 million in 2023, then plunged by 123.5% to -$10.7 million in 2024, then soared by 86.86% to -$1.4 million in 2025, then plunged by 707.13% to -$11.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$11.3 million (Q1 2026), -$1.4 million (Q4 2025), and -$6.2 million (Q3 2025), per Business Quant data.